Aura Biosciences Inc ((AURA)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aura Biosciences Inc (AURA) is conducting a Phase 3 clinical trial titled ‘A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma.’ This study aims to assess the safety and efficacy of belzupacap sarotalocan (bel-sar) in treating patients with primary indeterminate lesions or small choroidal melanoma, conditions that can lead to severe ocular complications.
The intervention being tested involves the administration of bel-sar, a drug delivered via a suprachoroidal microinjector followed by an infrared laser application. This treatment is compared against a sham control involving a sham injection and laser.
The study is designed as a randomized, double-masked, controlled trial with a parallel intervention model. Participants, outcomes assessors, and sponsors are masked to ensure unbiased results. The primary purpose of the study is treatment-focused.
The trial began on August 17, 2023, and is currently recruiting participants. The last update was submitted on September 9, 2025, indicating ongoing progress. The primary completion and estimated study completion dates have not been disclosed yet.
This update could potentially influence Aura Biosciences’ stock performance positively, as successful trial results may enhance the company’s market position in ocular oncology. Investors should monitor this study’s progress, considering the competitive landscape in the treatment of ocular melanoma.
The study is ongoing, with further details available on the ClinicalTrials portal.